AI-Driven Design Revolutionizes Biomolecule-Drug Conjugate Development for Gynecological Cancers

Gynecological cancers, including ovarian, cervical, and endometrial types, remain a significant cause of mortality, often developing drug resistance due to their diverse cellular and molecular characteristics. Traditional chemotherapy and even targeted therapies frequently face limitations in achieving sustained efficacy. Biomolecule-drug conjugates (BDCs), particularly antibody-drug conjugates (ADCs), offer a promising targeted approach by delivering cytotoxic payloads directly to cancer cells. However, their development has historically relied on resource-intensive, empirical methods, creating a bottleneck for optimizing specificity, efficacy, and safety.

This narrative review critically analyzed recent advances in machine learning (ML) and deep learning (DL) methods applied to biomolecule-drug conjugate (BDC) design for gynecological cancers. The authors summarized how AI can be leveraged to predict crucial parameters such as biomolecule-target binding affinity, structural compatibility, linker stability, and optimal payload selection. The review also explored the incorporation of structural, chemical, biological, and multi-omics data to enhance the specificity, efficacy, and safety of these conjugates. Beyond antibody-based systems, AI-assisted design approaches for peptide, aptamer, and hybrid biomolecular systems were also included in the analysis.

The review highlights AI's transformative potential in moving BDC development from a largely 'trial and error' approach to a more predictive and data-driven paradigm. AI-based methods can accurately predict biomolecule-target binding affinity, a critical factor for effective targeting, and assess structural compatibility to ensure stable conjugate formation. Furthermore, AI models are proving instrumental in optimizing linker stability, ensuring the drug payload is released effectively at the tumor site while minimizing systemic toxicity. The technology also aids in selecting the most potent cytotoxic payloads and predicting cellular trafficking and potential biomolecule resistance mechanisms. This integration of diverse data types, from structural to multi-omics, allows for a more rational and accelerated design process. The review emphasizes that AI can significantly enhance the specificity, efficacy, and safety profiles of BDCs, paving the way for more precise and personalized oncology treatments. This shift is crucial for overcoming the inherent drug resistance often observed in gynecological cancers.

AI-based conjugate engineering is increasingly moving BDC development from a largely 'trial and error' approach to a more predictive and data-driven approach.